Fiber Supplementation Lowers Plasma -Cresol in Chronic Kidney Disease Patients
To determine the effects of supplemental fiber on plasma p-cresol, stool frequency, and quality of life (QoL) in chronic kidney disease (CKD) patients.
PMID: 31701518 [PubMed - in process]
Authors: Kim MJ, Kim NY, Jung YA, Lee S, Jung GS, Kim JG, Lee IK, Lee S, Choi YK, Park KG Abstract Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated protective effects against diabetic kidney disease. However, the anti-fibrotic effect of evogliptin, a DPP-4 inhibitor, has not been studied. Here, we report the beneficial effects of evogliptin on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice. Evogliptin attenuated UUO-induced renal atrophy and tubulointerstitial fibrosis. Immunohistochemistry and We...
CONCLUSION: Hb level at>10 g/dL could be maintained for 8 weeks of treatment with both originator and biosimilar EPO (more consistent with originator EPO and more fluctuations with biosimilar EPO), with similar epoetin dose and no drug-related adverse event. PMID: 31699946 [PubMed - in process]
(JAMA Network) Whether a higher or lower dose of the muscle relaxant baclofen was associated with 30-day risk of hospitalization with encephalopathy (defined as a main diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack or an unclear diagnosis of dementia) among newly prescribed patients with chronic kidney disease was the focus of this observational study with nearly 16,000 older adults.
CONCLUSIONS: NLRP3, NLRP1 and AIM2 activation are involved in the progress of LN. NLRP3 activation has a positive correlation with the AI score of LN. PMID: 31694740 [PubMed - as supplied by publisher]
Publication date: December 2019Source: The Lancet Global Health, Volume 7, Issue 12Author(s): Jaya A George, Jean-Tristan Brandenburg, June Fabian, Nigel J Crowther, Godfred Agongo, Marianne Alberts, Stuart Ali, Gershim Asiki, Palwende R Boua, F Xavier Gómez-Olivé, Felistas Mashinya, Lisa Micklesfield, Shukri F Mohamed, Freedom Mukomana, Shane A Norris, Abraham R Oduro, Cassandra Soo, Hermann Sorgho, Alisha Wade, Saraladevi NaickerSummaryBackgroundRapid epidemiological health transitions occurring in vulnerable populations in Africa that have an existing burden of infectious and non-communicable diseases pred...
Publication date: December 2019Source: The Lancet Global Health, Volume 7, Issue 12Author(s): Tandi E Matsha, Rajiv T Erasmus
This pharmacoepidemiology study uses Canadian health care database data to estimate the risk of encephalopathy among patients with chronic kidney disease (CKD) in Ontario prescribed higher ( ≥20 mg) vs lower (
In conclusion, common chronic non-communicable diseases, including hypertension, diabetes, obesity, hyperhomocysteinemia, hyperuricemia, and hypertriglyceridemia, were associated with greater prevalence of CKD.
Hyperphosphatemia is an electrolytic disorder that may be of concern in the setting of tumor lysis syndrome (TLS), rhabdomyolysis, and metabolic acidosis. Furthermore, hyperphosphatemia occurs in advanced chronic kidney disease and hypoparathyroidism. In the acute setting, such as TLS, hyperphosphatemia can lead to consider renal replacement therapy.